T1	Participants 79 141	nondiabetic patients with stage I or II chronic kidney disease
T2	Participants 443 455	CKD patients
T4	Participants 736 848	Thirty nondiabetic stage I or II CKD patients who had already been treated with angiotensin II receptor blockers
T5	Participants 1805 1842	nondiabetic hypertensive CKD patients
